Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02051751 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase 1 study of Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 5
- Study locations
NCT02051751 is a Phase 1 study of Neoplasms, Breast Neoplasms, Head and Neck Neoplasms that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 19 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT02051751, a Phase 1 study of Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 5
- Study locations
Study Summary
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel combination
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG BYL719
Study Locations (5)
Arkansas
- Highlands Oncology Group - Fayetteville
Indiana
- Horizon Oncology Center BioAdvance - Lafayette
Other
- Novartis Investigative Site - Toulouse
MI
- Novartis Investigative Site - Milan
Catalonia
- Novartis Investigative Site - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-03-05 |
| Est. Completion | 2016-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02051751
The ClinicalTrials.gov registry entry for NCT02051751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Breast Neoplasms, Head and Neck Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02051751 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Indiana, Other.
Frequently Asked Questions
What is clinical trial NCT02051751 about?
NCT02051751 is a clinical study titled "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer". Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel combination
What is the current status of trial NCT02051751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-03-05. Estimated completion is 2016-08-19.
What conditions does trial NCT02051751 study?
This clinical trial studies the following conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms.
What interventions are being tested in trial NCT02051751?
The interventions under investigation include: Paclitaxel (DRUG), BYL719 (DRUG).
Who is sponsoring clinical trial NCT02051751?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02051751 being conducted?
This trial has 5 study locations across Arkansas, Indiana, MI, Catalonia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.